Volver a Agenda
Session Chair(s)
Steve Wilson, PHD
Senior Staff Fellow, OB, OTS, CDER
FDA, United States
Learning Objective : Contrast and critique some of the potential statistical approaches needed to address difficult evidentiary issues associated with the development and review of new medical products; Discuss the current thinking of industry and regulatory professionals in regards to strategic next steps to improve regulatory statistics; Describe an open, transparent framework for the collaborative development of innovative approaches to decision-making in a regulatory environment.
Speaker(s)
Panelist
H. M. James Hung, PHD
FDA, United States
Director, Division of Biometrics I, Office of Biostatistics, OTS, CDER
Panelist
Rima Izem, PHD
Novartis, Switzerland
Associate Director Statistical Methodology
Panelist
Lisa LaVange, PHD
University of North Carolina at Chapel Hill, United States
Professor Emerita
Panelist
Karen Lynn Price, PHD
Eli Lilly and Company, United States
Senior Research Fellow, Statistical Innovation Center/Design Hub
Panelist
Ram Tiwari, PHD, MS
Bristol Myres Squibb , United States
Head of Statistical Methodology
Panelist
Lilly Yue, PHD
U.S. FDA, United States
Deputy Director, Division of Biostatistics, CDRH/FDA
¿Tiene una cuenta?